Methamphetamine use disorders remain a significant public health concern. Methamphetamine produces its behavioral effects by facilitating release of monoamines like dopamine (DA) and serotonin (5-HT). Results from animal studies show that acute pretreatment with DA and 5-HT antagonists attenuates the effects of methamphetamine, but this area remains largely unexplored in humans. This study sought to assess whether aripiprazole, a partial agonist at D 2 /5-HT 1A receptors and an antagonist at 5-HT 2A receptors, would attenuate the reinforcing and subject-rated effects of oral methamphetamine. Seven subjects with histories of recreational stimulant use completed a placebo-controlled, crossover, double-blind protocol in which they first sampled doses of oral methamphetamine (0, 4, 8 or 16 mg) following acute pretreatment with aripiprazole (0 and 15 mg). During each Sampling Session, subjects also completed a battery of subject-rated, cardiovascular, and other performance measures. In subsequent Self-Administration Sessions, subjects were provided the opportunity to earn the previously sampled methamphetamine dose on a progressive-ratio procedure. Methamphetamine functioned as a reinforcer, and produced prototypical stimulant-like subject-rated and cardiovascular effects (e.g., increased ratings of Stimulated; elevated blood pressure). Aripiprazole reduced methamphetamine self-administration and attenuated some of the positive subject-rated effects of methamphetamine (e.g., ratings of Like Drug). These results indicate that acute aripiprazole pretreatment attenuates the abuse-related effects of methamphetamine.
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Introduction
Methamphetamine use remains a persistent public health concern. Data from the National Survey on Drug Use and Health (NSDUH) suggest that 439,000 Americans reported past-month methamphetamine use and 133,000 individuals indicated past-year initiation of methamphetamine use in 2011 (Substance Abuse and Mental Health Services Administration, 2012). Methamphetamine use is commonly associated with comorbid psychiatric problems and disorders, as well as needle sharing and risky sexual behaviors, which can lead to increased risk of contracting HIV (see Semple et al., 2004; Shoptaw et al., 2005 Shoptaw et al., , 2006 Zweben et al., 2004) . These risks highlight the need for a better understanding of methamphetamine abuse in humans.
Several in vitro and in vivo studies have demonstrated that dopamine (DA) and serotonin (5-HT) contribute to the behavioral effects of amphetamine in animals. A seminal preclinical study showed that dose-dependent enhancements in synaptic levels of DA and 5-HT were related to locomotor, sniffing, and stereotyped behavioral responses to amphetamine in rats (Kuczenski and Segal, 1989) . Additionally, Wee et al. (2007) found that acute pretreatment with aripiprazole, a partial agonist at D 2 /5-HT 1A receptors and an antagonist at 5-HT 2A receptors, reduced methamphetamine self-administration in rats. A number of preclinical drug-discrimination studies have implicated both central DA and 5-HT systems in mediating the behavioral effects of methamphetamine (Bergman, 2008; Czoty et al., 2004; Munzar and Goldberg, 2000; Munzar et al., 1999; Tidey and Bergman, 1998) . For example, in one of these previous studies, 10 squirrel monkeys were trained to discriminate methamphetamine (0.3 mg/kg) from saline (Tidey and Bergman, 1998) . A D 2 receptor agonist, (+)-PHNO, dosedependently increased methamphetamine-appropriate responding,
